DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

3.17 0.02 (0.63%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CYCC $3.17 0.63%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.14
Previous Close $3.15
Daily Range $3.08 - $3.17
52-Week Range $2.88 - $5.50
Market Cap $71.9M
P/E Ratio -3.50
Dividend (Yield) $0.00 (0.0%)
Volume 60,072
Average Daily Volume 71,615
Current FY EPS -$1.06

Sector

Healthcare

Industry

Drugs

CYCLACEL PHARMACEUTICALS, INC. (CYCC) Description

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Website: http://www.cyclacel.com/

News & Commentary

Cyclacel Announces New Stock Issue

The pharmaceutical company hopes to reap gross proceeds of around $20 million from the offering.

Cyclacel Pharma Reports CYC065 CDK Inhibitor Shows Terapeutic Potential in Acute Leukemias with MLL

Cyclacel Pharma Reports CYC065 CDK Inhibitor Shows Terapeutic Potential in Acute Leukemias with MLL Rearrangements

With Cyclacel, The Waiting Is The Hardest Part

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q2 2014 Results - Earnings Call Transcript

Cyclacel Shapes Sapacitabine's Phase IIb Study For Regulatory Success

Cyclacel Pharmaceuticals: The Devil's Advocate Be Damned

Morning Market Losers

Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2014 Results - Earnings Call Transcript

The Incredible Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering

Benzinga's Top #PreMarket Losers

See More CYCC News...

CYCC's Top Competitors

CYCC $3.17 (0.63%)
Current stock: CYCC
AMGN $144.01 (1.40%)
Current stock: AMGN
GILD $105.96 (0.03%)
Current stock: GILD
BIIB $329.24 (-0.23%)
Current stock: BIIB